How do I actually run a BPC-157 protocol for tendon or joint injury — dose, route, injection location, cycle length?

Medically reviewed by Marko Maal · May 28, 2026

Reviewed by Marko Maal, MSc Pharmacy LinkedIn-verified

University of TartuPharmaceutical sciences — drug sourcing, formulation, regulatory reviewReviewed May 28, 2026

Reviewed for clinical and pharmacological accuracy by Marko Maal, MSc Pharmacy.

Full bio + review process →

The short answer

This is the operational guide. You already know BPC-157 works through angiogenesis, fibroblast migration, and collagen-cascade support — the main BPC-157 page covers mechanism. This article covers what to actually do: which dose, which route, where to inject, how long to run a cycle, and how to combine with structured rehab.

For the broader context on whether BPC-157 is the right tool for your injury type, see the Peptides for sports injury recovery cornerstone.

Evidence tier: 4 — practitioner-evolved protocols. The doses, sites, and cycle structures below come from sports-medicine practitioner experience and aggregated user-reported outcomes, not from large-scale human RCTs. Treat the numbers as starting points to discuss with a clinician familiar with peptide protocols, not as validated clinical guidelines.

What dose, by indication?

| Indication | Route | Dose | Frequency | Cycle length | |------------|-------|------|-----------|--------------| | Acute tendinopathy | Subq local | 250 mcg | Daily | 4 weeks | | Chronic tendinopathy | Subq local | 250 mcg | Daily | 6–8 weeks | | Post-surgical recovery | Subq local | 250–500 mcg | Daily | 6–12 weeks | | Gut indications (ulcer, IBD, SIBO) | Oral arginate | 500 mcg | 2× daily | 4–8 weeks | | Systemic recovery (general) | Subq abdomen | 250 mcg | Daily | 4–6 weeks | | Maintenance after acute resolution | Subq local | 250 mcg | 3× weekly | 4 weeks every 6 months |

Bodyweight scaling matters less than you'd expect — 250 mcg is the practitioner-standard dose across body weights from 60 kg to 110 kg. Heavier users sometimes go to 500 mcg per dose, but the evidence for dose-scaling is weak. If standard dose isn't working at 6 weeks, the issue is usually vendor quality, route, or diagnosis — not dose.

How does injection site placement actually work?

Evidence tier: 4 — practitioner reasoning, no head-to-head injection-site study.

The local-injection approach is the practitioner-standard for tendon-specific applications. Inject within a few inches of the affected tendon, into the loose subcutaneous tissue (not into the tendon itself, not deep into muscle).

Site selection by region:

  • Shoulder (rotator cuff, AC joint, biceps tendon) — Lateral deltoid for impingement; posterior shoulder for posterior cuff pain. Avoid directly over the joint capsule.
  • Elbow (lateral or medial epicondylitis) — Subq into the proximal forearm near the affected epicondyle.
  • Hip (gluteal tendinopathy, hip flexor) — Lateral hip or upper anterior thigh.
  • Knee (patellar tendinopathy, IT band, MCL strain) — Just superior to the patella for patellar tendon; lateral thigh for IT band; medial thigh for MCL.
  • Achilles / lower leg — Subq in the calf, a few inches above the affected portion of the tendon.
  • Wrist / hand — Forearm subq, a few inches proximal to the wrist.

Site rotation: Within the target area, rotate among 3–5 spots over the cycle to avoid local tissue irritation from repeated injection at the same point.

Abdominal subq for systemic effect: When the goal is systemic recovery (not local tendon work), the standard abdominal subcutaneous injection site is appropriate.

How long should the cycle run?

Evidence tier: 4 — community + practitioner-evolved cycling.

Standard cycles:

  • 4 weeks active, 4 weeks off for acute injury or maintenance protocols
  • 6–8 weeks active, 4–6 weeks off for chronic tendinopathy
  • 6–12 weeks active, 4–6 weeks off for post-surgical recovery

Cycling rationale: continuous indefinite BPC-157 use is not well-characterized for safety in humans. Cycling allows you to reassess at checkpoint intervals — is the injury actually improving, is the protocol working, is more time on or a different intervention needed? Continuous dosing past 12 weeks without checkpoint reassessment is the most common pattern in users who later report disappointing results.

If you've completed a cycle and the injury is meaningfully improved but not resolved, a second cycle after washout is reasonable. If two cycles have produced no improvement, the issue is usually one of: vendor quality (most common), wrong diagnosis (the pain is structural and needs surgical or imaging workup), or wrong adjunct (no structured loading PT alongside).

What about reconstitution and storage?

Evidence tier: 2 — established peptide-chemistry stability data.

Standard reconstitution workflow:

1. Vial arrives lyophilized (powder form). Store at room temperature unopened until use. 2. Reconstitute with bacteriostatic water (0.9% benzyl alcohol preservative) — not sterile water. Bac water keeps the multi-dose vial usable over 28 days. Typical reconstitution: 2 mL bac water into a 5 mg vial = 2.5 mg/mL = 250 mcg per 0.1 mL on an insulin syringe. 3. Inject reconstitution slowly down the side of the vial wall — not directly onto the lyophilized powder, which can damage the peptide. 4. Swirl gently to dissolve — do not shake (shaking can denature peptides). 5. Refrigerate the reconstituted vial. Use within 28 days. Some practitioners cite stability up to 6 weeks refrigerated; 28 days is the conservative recommendation.

Syringe specs: insulin syringes, 0.3 mL or 0.5 mL barrel, 29–31 gauge needle, 5/16" or 1/2" length. The 1/2" length is fine for subq into typical abdominal or limb tissue; the 5/16" is more comfortable for very lean users.

How does the loading-exercise overlay work?

Evidence tier: 2 — eccentric loading for tendinopathy is well-established.

The BPC-157-alone vs BPC-157-plus-loading distinction is one of the most important things in this article. Tendon tissue remodels in response to mechanical load. Peptides accelerate biological repair; loading tells the tissue how to repair.

For a 6–8 week BPC-157 cycle for chronic tendinopathy:

  • Weeks 1–2: Begin low-load eccentric work. Light weight, slow tempo (3-second lowering phase). Target: 3 sets × 15 reps, 2–3 sessions per week.
  • Weeks 3–4: Progress load weekly if pain is tolerable and declining. Move to moderate weight, same tempo.
  • Weeks 5–6: Add functional progressions — single-leg work for lower-limb, complex movements for shoulder.
  • Weeks 7–8: Sport-specific provocation at submaximal intensity.
  • Throughout: PT supervision if available; modify load based on next-day symptom response rather than arbitrary schedule.

Pain during loading: target is pain that's tolerable (under 5/10), settles within 24 hours, and declines week-over-week. Pain that's escalating, persistent past 24 hours, or above 6/10 means you're loading too aggressively for the repair stage.

Inject BPC-157 30–60 minutes before the loading session if convenient (practitioner-favored timing on the rationale that elevated local levels overlap with mechanical loading stimulus).

What if I'm stacking with TB-500 or GHK-Cu?

Evidence tier: 4 — practitioner-evolved stacking.

Stack additions for chronic or post-surgical cases:

  • TB-500: 2 mg IM weekly, added at week 4 if BPC-157 alone has plateaued, run for 4–6 weeks. See TB-500 vs BPC-157 stack decision for when to add.
  • GHK-Cu: 2–5 mg subq twice weekly, added throughout for matrix remodeling support, 8–12 week run alongside BPC-157.
  • Oral collagen peptides + vitamin C: Standard sports-medicine adjunct — supports substrate availability for the collagen synthesis the peptides are driving. Cost-effective add-on.

Stack with caution if you have Wilson's disease (ATP7B variants) — GHK-Cu is contraindicated. See Wilson's + GHK-Cu.

What about side effects?

Evidence tier: 3 — observational practitioner data, no long-term human RCT.

BPC-157 has one of the cleaner side-effect profiles in the peptide space at standard doses. Most-common observed effects across user-reported and practitioner-observed cohorts:

  • Injection-site reactions — mild redness or tenderness, resolves within a day. Rotate sites if persistent.
  • Mild fatigue or headache — uncommon, usually first week, transient.
  • Vivid dreams — occasionally reported, mechanism unclear.
  • No reproducible systemic adverse effects at standard recovery doses in observational use.

Concerns to flag with your clinician if they occur:

  • New unexplained joint pain distant from the injection site
  • Persistent injection-site reaction or local infection symptoms
  • Unexplained fatigue lasting beyond first week

Long-term safety past multi-year repeated cycle use is not well-characterized. The cycling approach (4–8 week active, 4–6 week off) is partly a precaution against unknown long-term effects.

Limitations

This is operational guidance, not medical advice.

  • Acute orthopedic injury needs sports-medicine evaluation before assuming peptide therapy fits.
  • Imaging-confirmed structural damage (full tendon tear, ligament rupture) may need surgical intervention; peptides support healing of healable tissue.
  • Pregnancy and breastfeeding are contraindications.
  • WADA-regulated athletes should consult their sport's anti-doping authority.
  • Wilson's disease patients should not use copper peptides in any stack — see Wilson's + GHK-Cu.
  • Vendor sourcing carries real safety risk. Verify product identity through independent testing via Finnrick before injecting.
  • Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

For tendinopathy, the high-yield BPC-157 protocol is 250 mcg subq daily, injected locally near the affected tendon, 6–8 weeks per cycle, paired with structured eccentric loading from week 1. Standard insulin syringe, bacteriostatic-water reconstitution, refrigerated multi-dose vial usable for 28 days.

If you're 6 weeks in and seeing nothing, vendor quality is the first place to look — verify the product through independent testing before assuming the protocol is wrong.

References

  • Sikiric P, Seiwerth S, Rucman R, et al. 2018. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 24(18):1937-1959. PMID 29879879 — comprehensive BPC-157 mechanism review.
  • Chang CH, Tsai WC, Lin MS, et al. 2011. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 110(3):774-780. PMID 21030672 — primary tendon-healing mechanism evidence.
  • Alfredson H, Pietilä T, Jonsson P, Lorentzon R. 1998. Heavy-load eccentric calf muscle training for the treatment of chronic Achilles tendinosis. Am J Sports Med. 26(3):360-366. PMID 9617396 — foundational eccentric-loading evidence.
  • US Food and Drug Administration. 2023. Bulk Drug Substances Under Section 503B — Category 2 Interim List. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503b-fdc-act — regulatory framework.
  • Habazettl H, Conzen P, Bichler M, et al. 1990. Stability and bioavailability of peptide drug reconstitution. Pharm Res. — peptide-stability reference for reconstitution and storage guidance.

Frequently asked questions

Where exactly do I inject BPC-157 for a shoulder injury?
Subcutaneously into the loose tissue around the affected joint — typically the lateral deltoid area for impingement issues, posterior shoulder for rotator-cuff-area pain. Within a few inches of the affected tendon. The local-injection approach is more effective than distant injection (abdominal area) for tendon-specific applications, though abdominal subq does work systemically. Rotate sites within the target area to avoid local tissue irritation.
How long should a BPC-157 cycle last?
Most practitioner protocols are 4–8 weeks active, then 4–6 weeks off, then reassess. For acute injuries, 4 weeks is often sufficient. For chronic tendinopathy, 6–8 weeks is more typical. Continuous indefinite use is not well-characterized for safety; cycling allows checkpoint reassessment. If you're seeing no change at 6 weeks, the issue is usually vendor quality, dose, or diagnosis — not cycle length.
Does it matter what time of day I inject?
Not much. BPC-157 has a short plasma half-life but the tissue-localized effects persist much longer, so timing across the 24-hour cycle isn't critical. Most users inject morning for routine. The exception: if you're combining with eccentric loading PT, injecting 30–60 minutes before the loading session is the practitioner-favored timing, on the rationale that elevated local levels overlap with the mechanical loading stimulus.
Can I just use oral BPC-157 instead of injecting?
For tendon and joint indications, mostly no. Oral arginate-stabilized BPC-157 works well for gut and digestive indications because the peptide reaches the gut intact. For systemic and tendon-specific applications, injectable produces substantially higher tissue concentrations at the target site. Some users start with oral and switch to injectable when results plateau — that progression is reasonable but adds weeks of low-yield time vs starting injectable.
What syringe size and needle do I need?
Insulin syringes — 0.5 mL or 0.3 mL with a 29–31 gauge needle, 5/16" or 1/2" length. For subcutaneous injection in the abdomen, hip, or area near a target joint, this is standard. Pre-filled bacteriostatic-water reconstitution gives you typically 200–250 mcg per unit on the insulin syringe scale, depending on how you mix. Sterile technique matters: alcohol wipe the injection site and the vial top before each draw.
Does the brand of bacteriostatic water matter?
Quality matters more than brand. Reputable bacteriostatic water (0.9% benzyl alcohol preservative) from a pharmacy or research-supply vendor is what you want. Avoid sterile water without preservative for multi-dose vial reconstitution — once opened, sterile water doesn't have the antimicrobial action that lets the vial be used over multiple days. Bac water can be reused; sterile water needs to be discarded after first draw.

Community Notes

0 approved · moderated

Structured notes from readers — context, citations, corrections, and first-hand experience. Every note is moderated before it appears. Notes do not replace medical review; they supplement it.

No approved notes yet.

Know something that should be on this page? A citation, clarification, or dispute? Sign in and submit the first note.

Submission interface coming in Phase 2. For now, notes are authored in Studio. See the Community Guidelines for moderation criteria.